Therapy of Chronic Myelogenous Leukemia With Recombinant Interferon

Recently. we reported that recombinant interferon-a (rIFN-a) can induce hematologic remissions and cytogenetic improvement in newly diagnosed Philadelphia (Ph)positive chronic myelogenous leukemia (CML) patients. Although IFN-”y is a structurally distinct molecule. this agent suppresses in vitro hematopoietic progenitor cells in a fashion similar to that of… CONTINUE READING